What is the fair value of ABT stock?

Our analysis estimates the fair value range for ABT to be between $99.30 and $103.55. The current price is $102.51.

What is the analyst price target for ABT?

The average Wall Street analyst price target for ABT is $120.41. This implies a potential upside of 17.5% from current levels.

Abbott Laboratories (ABT) Stock: Buy, Sell, or Hold?

ABT - Abbott Laboratories

PHARMACEUTICAL PREPARATIONS

$102.51

2.00 (1.99%) ▲

5d: -2.07%

30d: -0.95%

90d: -0.53%

WAIT

LOW Confidence

Protect Your ABT Gains

Analysis Updated: Oct 22, 2026 12:00 AM ET

Earnings: Oct 21, 2026 0d

Smart Money Accumulation

Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →

Signal fired Oct 20, 2026 at $101.15 · last confirmed Oct 22, 2026

Strength: 7.0/10

Get Alerted When ABT Hits Your Target Price

Join 10,000+ traders who never miss a move

You're in! Check your email to confirm and set your target price.

100% Free No spam, ever Unsubscribe anytime

Interactive Price Chart (1 Month)

Loading historical data...

💡

Bottom Line:
ℹ️ NEUTRAL: ABT is fairly priced but lacks strong directional signals. At -0.9% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.

See Forward Earnings Fair Value & Price Prediction →

Long-Term Wealth Forecast (2031)

Based on Analyst Consensus Growth & Historical Valuation

Adjust Growth Assumption: 9.6%

0% (Stagnation) 50% (Hyper Growth)

EST. PRICE IN 2031

$146.04

Based on 6.8% avg growth

INTRINSIC VALUE TODAY

$90.68

Trading above historical range

How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 17.4x Exit PE.

View Full DCF Model

In-depth Analysis How we analyze

Valuation Analysis: ABT is currently trading at $102.51, which is considered slightly high relative to its 30-day fair value range of $99.30 to $103.55. The stock's valuation (Forward PE: 17.0) is in line with its historical norms (17.4). Remarkably, the market is currently pricing in an annual earnings decline of 0.9% over the next few years. This aligns with recent fundamental challenges.

Technical Outlook: Technically, ABT is in a uptrend. Immediate support is located at $97.67, while resistance sits at $106.35.

Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $120.41 (+17.5%). Current signals suggest waiting for a better entry point before initiating new positions.

Quick Decision Summary

Current Position SLIGHTLY HIGH

Historical Trading Range $99.30 - $103.55

Company Quality Score 50/100 (HOLD)

Volume Confirmation HIGH

Confidence Score 62.9%

Protect Your Profits

Holding ABT? Use our AI-powered strategies to protect your downside while keeping your long-term position.

View Profit Protection Plan

All Signals

NEUTRAL: Mixed technical signals (44/100)
BULLISH: High volume confirmation
BULLISH: Trading below Wall St target ($120.41)
WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market

Trading Range Analysis

30-Day Trading Range $99.30 - $103.55

Current vs Trading Range SLIGHTLY HIGH

Support & Resistance Levels

Support Level $97.67

Resistance Level $106.35

Current Trend Uptrend

Technical data as of Oct 22, 2026

Fundamental Context

Forward P/E (Next Year Est.) 16.96

Wall Street Target $120.41 (+17.5%)

Revenue Growth (YoY) 13.0%

Earnings Growth (YoY) -47.5%

Profit Margin 11.7%

Valuation Discount vs History -0.9% cheaper

PE vs Historical 17.0 vs 17.4 FAIR

Market-Implied Price Targets If current PE multiple persists

Implied Growth (YoY): -0.9% (market-implied from PE analysis)

1-Year Target $101.59 (-1%)

2-Year Target $100.67 (-2%)

3-Year Target $99.77 (-3%)

3-Yr Target (if PE normalizes) (PE: 17→17) $102.38 (0%)

3-Year Scenarios Using analyst projected EPS growth

Bull: (PE: 19.9, Growth: 9.6%) $157.89 (+54%)

Base: (SPY PE: 17.0, Growth: 9.6%) $134.80 (+32%)

Bear: (PE: 14.4, Growth: 9.6%) $114.58 (+12%)

📈 Valuation based on Current Earnings

RECOVERY PLAY: Stock looks expensive now (37x PE), but valuation improves significantly next year (17x PE) as earnings recover.

Trailing PE: 37.36 | Current EPS (TTM): $2.69

Bull Case $221.12 (+116%)

Analyst growth 100.0%, PE expands to 41.1

Base Case $201.02 (+96%)

Market implied 100.0%, PE stable at 37.4

Bear Case $68.35 (-33%)

Severe decline -20.0%, PE contracts to 31.8

These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.

💡 Upside Surprise Potential

If earnings stabilize (0% growth), PE could expand from 17.0 to 17.4

Stabilization Target: $105.20 (+2.6%)

PE Expansion Potential: +2.6%

Share & Embed Analysis

Found this analysis useful? Share it with your community or embed the live chart on your blog.

Tweet Reddit

bloggers & journalists: you are free to use our charts with attribution.

Last updated: October 23, 2026 7:31 AM ET
Data refreshes hourly during market hours. Next update: 8:31 AM

🔥 Top Stocks Breaking Out Now

Ticker	Score	Recommendation	Change %

See Full Scanner Results »

Technical Signals Check

Is ABT showing a specific setup today?

RSI Divergence Check TTM Squeeze Check MACD Crossover Check Gamma Walls Check Unusual Activity Check

Insider Activity (6 Months)

Buys

Sells

Net

NEUTRAL

View Insider Activity Scanner

Unlock Insider Activity

See real-time buying/selling by company executives for ABT.

Create Free Account

Already have an account? Log In

Featured in Portfolios

ABT is a key holding in these high-performance investment strategies.

Healthcare Recovery Score Based • -24.6% Return

Healthcare Improvers Score Based • +50.5% Return

MedTech Improvers Score Based • -16.6% Return

Steady Improvers Score Based • -19.4% Return

Rocket Ships Score Based • -8.5% Return

Top 20 Improvers Score Based • -1.5% Return

View All Strategies

Top Rated Medical Devices Stocks

Top-rated stocks in Medical Devices by analyst ratings.

Stock	Analyst Consensus	Analyst Target	Tradestie Score
DXCM DexCom Inc	STRONG BUY 29 analysts	$96	45 HOLD
EW Edwards Lifesciences Corp	STRONG BUY 29 analysts	$102	51 HOLD
SYK Stryker Corporation	STRONG BUY 29 analysts	$363	32 SELL
AXGN Axogen Inc	STRONG BUY 12 analysts	$54	73 BUY
GEHC GE HealthCare Technologi…	STRONG BUY 21 analysts	$83	39 SELL

DXCM DexCom Inc

45 HOLD

EW Edwards Lifescien…

51 HOLD

SYK Stryker Corporati…

32 SELL

AXGN Axogen Inc

73 BUY

GEHC GE HealthCare Tec…

39 SELL

Advanced ABT Option Strategies

Professional options setups generated by AI based on today's ABT price and gamma walls.

Iron Condor Bull Call Bear Put Collar

More Analysis for ABT

ABT Technical Chart ABT Price Prediction ABT Earnings Date ABT Investment Advisor ABT Fair Price Analyzer ABT Options Advisor ABT Options Chain ABT Options Analysis ABT Competitors

Compare ABT with Peers

ABT vs ABBV
Which one to buy?

ABT vs BMY
Which one to buy?

ABT vs JNJ
Which one to buy?

ABT vs MDT
Which one to buy?

ABT vs LLY
Which one to buy?

XENE vs ABT
Winner: ABT

UNOV vs ABT

SPRB vs ABT
Winner: ABT

KROS vs ABT
Winner: ABT

Create New Comparison View All Competitors

Tradestie